New Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay.

"Conflict of Interest: R.D.K. is the co-founder of and holds a significant financial interest in AIM Biotech, a company that produces microfluidic devices. R.D.K. also receives research support from Amgen, Novartis, Boehringer Ingelheim, GSK, AbbVie, and Roche. D.A.B. is a co-founder of and holds a significant financial interest in Xsphera Biosciences, and is a consultant for Qiagen/N of One. D.A.B. has also received research funding from Novartis, Gilead Sciences, BMS, and Lilly Oncology."

"Z.W. and M.F. contributed equally to this work. Z.W. is supported by a Ludwig Center Fund Post-Doctoral Research Fellowship from the Koch Institute for Integrative Cancer Research and by National Cancer Institute (U01 CA214381). C.X. is supported by funds from National Natural Science Foundation of China (81903158 and 32170940), Guangzhou Science and Technology Project (201904010042), and Guangdong Natural Science Foundation (2022A1515012658). This work was supported by a National Cancer Institute Physical Sciences-Oncology Network supplement to award U01 CA214381. The PBMCs were kindly provided by Prof. Bryan Bryson. This work was supported in part by the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute."